MAPT and Alzheimer disease: Because studies confirming neurological/pathologic changes, including changes in the inflammatory cytokines, Aβ, tau level, and neural circuits in the central nervous system, are insufficient, it is difficult to show the mechanisms by which AAI alleviates AD-related pathologies; however, in this review, we highlighted the value of AAI as a non-pharmacological intervention through the hypothesis that AAI may also affect AD-related pathologies and presented insights for future studies.